Design Therapeutics, Inc.

NASDAQ:DSGN

4.84 (USD) • At close February 4, 2025
Bedrijfsnaam Design Therapeutics, Inc.
Symbool DSGN
Munteenheid USD
Prijs 4.84
Beurswaarde 274,045,640
Dividendpercentage 0%
52-weken bereik 2.245 - 7.77
Industrie Biotechnology
Sector Healthcare
CEO Mr. Pratik Shah Ph.D.
Website https://www.designtx.com

An error occurred while fetching data.

Over Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to

Vergelijkbare Aandelen

Erasca, Inc. logo

Erasca, Inc.

ERAS

1.78 USD

Cross Country Healthcare, Inc. logo

Cross Country Healthcare, Inc.

CCRN

18.18 USD

POINT Biopharma Global Inc. logo

POINT Biopharma Global Inc.

PNT

12.5 USD

uniQure N.V. logo

uniQure N.V.

QURE

15.91 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

5.83 USD

Replimune Group, Inc. logo

Replimune Group, Inc.

REPL

14.01 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.882 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)